StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
CMPS$14.19+8.65%
Fair $14.19+0.0%

CMPS

COMPASS Pathways plc

Healthcare / Medical Care FacilitiesNasdaqGS

$14.19

+1.13 (+8.65%)

Fairly Valued+0.0%Fair Value $14.19Fund rank 31/100 · Data gapFallback financials|
SA 39/D
F-Score: 2/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-119.2M · quality 68.7/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 40/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

39/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 7Warnings: 0unknown: 7
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · CMPSLocal privado en este navegador · COMPASS Pathways plc
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.9B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

544.7%

↑

Gross Margin

N/A

•

Debt/Equity

-0.66

↓
52-Week Range$14
$2$15

TradingView lightweight chart

CMPS price, volumen y niveles de valoración

Último $14.19Periodo -51.1%
Fair value: $14.19

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2019–2025 · 6 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

0.55x

Latest source

Provider fallback

Margin decomposition

Último año: revenue — · net income $-287.9M · FCF $-157.2M

2019-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

—— pts

FCF margin

—— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
Income Statement
Net Income$-287.9M$-287.9M$-155.1M$-118.5M$-91.5M$-71.7M$-60.3M$-19.6M
EBITDA$-285.6M$-285.6M$-148.8M$-115.2M$-90.8M$-83.0M$-51.3M$-21.1M
EPS-3.08-3.08-2.30-2.32-2.16-1.79-3.55-2.62
Balance Sheet
Debt/Equity-0.66-0.660.210.150.01———
Current Ratio3.323.32——————
Cash Flow
Free Cash Flow$-157.2M$-157.2M$-119.2M$-97.4M$-106.0M$-68.1M$-41.5M$-18.0M
Returns
ROE544.7%544.7%-100.3%-52.5%-50.5%-25.2%-30.7%64.5%
Valuation
P/B——1.942.671.71———
Growth & Yield
EPS Growth-33.9%-33.9%0.9%-7.4%—49.6%-35.5%—

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +241.1%

Total return

+241.1%

Start / end P/E

n/dx → n/dx

EPS bridge

-2.30 → -3.08

Residual

+241.1%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+241.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.